MUMBAI (Reuters) - Indian drugmaker Aurobindo Pharma Ltd said it agreed to buy Actavis Plc's commercial operations in seven Western European countries for about 30 million euros, in a bid to increase its international footprint.
Aurobindo said the deal would include commercial infrastructure, products and marketing authorizations in the seven countries. The two companies will also enter a long-term commercial and supply deal to support the growth plans of the businesses.
Although the businesses are currently loss-making, Aurobindo expects them to return to profitability, the company said in a statement.
(Reporting by Aradhana Aravindan; Editing by Clarence Fernandez)
You’ve reached your limit of 5 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app